{"id":"W2140587309","doi":"10.1016/s1470-2045(12)70490-4","title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":550,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto General Hospital; Vancouver General Hospital","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Hepatocellular carcinoma; Sorafenib; Population; Neutropenia; Performance status; Randomized controlled trial; Surgery; Oncology; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009615795,0.0002023123,0.001783455,0.00005799876,0.00009072544,0.000001285326,0.0001242459,0.0001449277,0.0002528419],"category_scores_gemma":[0.0001379387,0.0001127894,0.0002359401,0.00006854621,0.0001684675,0.00003646159,0.00002756377,0.0001295482,0.00002226192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000708306,"about_ca_system_score_gemma":0.0001299008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009456963,"about_ca_topic_score_gemma":0.000009701602,"domain_scores_codex":[0.9982158,0.0006058103,0.0004270694,0.0002154981,0.00006823176,0.0004676245],"domain_scores_gemma":[0.9976687,0.001436433,0.000268743,0.0004525882,0.00008222817,0.00009133617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8136836,0.01278454,0.066107,0.0001105951,0.001275733,0.00009063624,0.009616604,0.00000711309,0.08985066,0.0004298319,0.0007087139,0.005334919],"study_design_scores_gemma":[0.9252228,0.02911299,0.008361223,0.000008420311,0.001503559,0.0001360754,0.001090683,0.0002890015,0.01492295,0.0001638703,0.01903565,0.0001527917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890679,0.001302614,0.00009588098,0.0007163956,0.000505796,0.006454702,0.00004556308,0.0000335022,0.001777628],"genre_scores_gemma":[0.9953263,0.00004409209,0.0004186038,0.000414492,0.001189796,0.001490456,0.00005073952,0.00001947465,0.001046082],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1115391,"threshold_uncertainty_score":0.4599418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0695716841107646,"score_gpt":0.374972235833241,"score_spread":0.3054005517224764,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}